Safety evaluation of axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma.

Nath, Karthik; Wudhikarn, Kitsada; Alarcon Tomas, Ana; Perales, Miguel-Angel

Nath, Karthik; Wudhikarn, Kitsada; Alarcon Tomas, Ana; Perales, Miguel-Angel.

Afiliación

Nath K; Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Wudhikarn K; Division of Hematology and Center of Excellence in Translational Hematology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Alarcon Tomas A; Division of Hematology and Hemotherapy, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
Perales MA; Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Expert Opin Drug Saf ; 22(1): 5-15, 2023 Jan.

Article en En | MEDLINE | ID: mdl-36737060

Asunto(s)

Linfoma de Células B Grandes Difuso; Receptores Quiméricos de Antígenos; Humanos; Inmunoterapia Adoptiva/efectos adversos; Resultado del Tratamiento; Linfoma de Células B Grandes Difuso/patología; Linfoma de Células B Grandes Difuso/terapia; Antígenos CD19/efectos adversos

Palabras clave

Axicabtagene ciloleucel; chimeric antigen receptor (CAR) T-cell therapy; cytokine release syndrome (CRS); immune effector cell-associated neurotoxicity syndrome (ICANS); large B-cell lymphoma (LBCL)

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Linfoma de Células B Grandes Difuso / Receptores Quiméricos de Antígenos Límite: Humans Idioma: En Revista: Expert Opin Drug Saf Asunto de la revista: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google